Quotes 5-day view Delayed Nasdaq
1 457 243
Estimated financial data (e) (USD)
Net income 2021
Net cash position 2021
P/E ratio 2021
Net income 2022
Net cash position 2022
P/E ratio 2022
1 194 M
1 194 M
EV / Sales 2021
EV / Sales 2022
Nbr of Employees
ImmunoGen, Inc. is a clinical-stage biotechnology company focused on developing the antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Companyâ€™s technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates...
Ratings of ImmunoGen, Inc.
All news about IMMUNOGEN, INC.
10/14 IMMUNOGEN : Announces Conference Call to Discuss Its Third Quarter 2021 Operating Results
10/01 IMMUNOGEN : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/23 IMMUNOGEN, INC. : Change in Directors or Principal Officers (form 8-K)
09/22 IMMUNOGEN : Appoints Helen M. Thackray, MD to its Board of Directors
09/22 ImmunoGen Inc. Appoints Helen M. Thackray, MD to its Board of Directors
08/12 IMMUNOGEN : Securities Purchase Agreement (Form 8-K)
08/12 IMMUNOGEN, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Fi..
08/02 IMMUNOGEN : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/30 IMMUNOGEN : Management's Discussion and Analysis of Financial Condition and Results of Ope..
07/30 IMMUNOGEN : Reports Recent Progress and Second Quarter 2021 Financial Results (Form 8-K)
07/30 IMMUNOGEN : Posts Wider Q2 Loss, Higher Revenue
07/30 IMMUNOGEN : Q2 Earnings Snapshot
07/30 IMMUNOGEN, INC. : Results of Operations and Financial Condition, Financial Statements and ..
07/30 Immunogen, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
07/30 IMMUNOGEN : Earnings Flash (IMGN) IMMUNOGEN Posts Q2 Revenue $16.9M
News in other languages on IMMUNOGEN, INC.
Analyst Recommendations on IMMUNOGEN, INC.
Technical analysis trends IMMUNOGEN, INC.
Short Term Mid-Term Long Term Trends Neutral Bearish Bearish
Number of Analysts
Last Close Price
Average target price
Spread / Average Target